ESMO Handbook: Clinical Pharmacology of Anti-Cancer Agents - Editors and Contributors

Editors

Cristiana Sessa
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy

Luca Gianni
Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy

Marina Garassino
Oncology Department, Istituto Nazionale dei Tumori, Milan, Italy

Henk van Halteren
Department of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands

Contributors

Chapter 1: Preclinical Drug Development: Translating Basic Research into Clinical Work

Stathis A. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Siu L.L. Drug Development Program, Princess Margaret Hospital, Toronto, Canada

Le Tourneau C. Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France

Chapter 2: Pharmacokinetics and Pharmacodynamics: Main Concepts and Clinical Applications

Calvert A.H. UCL Cancer Institute, University College London, London, UK

Chapter 3: Alkylating Agents

Damia G. Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

Garassino M. Oncology Department, Istituto Nazionale dei Tumori, Milan, Italy

Chapter 4: Platinum Agents

Razak A.R.A. Drug Development Program, Princess Margaret Hospital, Toronto, Canada

Calvert A.H. UCL Cancer Institute, University College London, London, UK

Chapter 5: Antimetabolites

Martínez M.T. Department of Hematology and Medical Oncology; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain

Roselló S. Department of Hematology and Medical Oncology; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain

Cervantes A. Department of Hematology and Medical Oncology; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain

Chapter 6: Topoisomerase-I and –II Inhibitors

Locatelli A. Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy

Viganò L. Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy

Chapter 7: Tubulin-active Agents

Le Tourneau C. Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France

DiéRas V. Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France

Chapter 8: Miscellaneous

Christinat A. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Chapter 9: Hormonal Pathways Modulators of the Reproductive System

Tosi D. Medical Oncology Department, CRLC Val d’Aurelle-Paul Lamarque, Montpellier, France

Durigova A. Medical Oncology Department, CRLC Val d’Aurelle- Paul Lamarque, Montpellier, France

Barrière J. Centre Antoine Lacassagne, Nice, France

Chapter 10: Growth Factor Receptor Targeting: Anti-HER and Anti-IGF-IR

Dienstmann R. Vall d’Hebron Institute of Oncology, Barcelona, Spain

De Dosso S. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Tabernero J. Vall d’Hebron Institute of Oncology, Barcelona, Spain

Chapter 11: Tumour Vessel Targeting

Del Conte G. Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy

Chapter 12: Downstream Receptor Targeting: P13K, mTOR, K-ras, BRAF, MEF

Fasolo A. Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy

Chapter 13: Cancer-related Receptor Targeting: Bcr-Abl, KIT, MET

Rusconi P. Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

Broggini M. Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

Chapter 14: Epigenetic Therapy: DNA Methyltransferase Inhibitors and Histone Deacetylase Inhibitors

Stathis A. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Lobetti-Bodoni C. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Catapano C. Institute of Oncology Research, Bellinzona, Switzerland

Chapter 15: Proteasome Inhibitors

Driessen C. Interdisziplinare Medizinische Dienste, Kantonsspital St Gallen, St Gallen, Switzerland

Chapter 16: Monoclonal Antibodies for Targeted Treatment of Lymphoproliferative Neoplasias

Guidetti A. Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan; Medical Oncology, University of Milan, Milan, Italy

Giacomini A. Medical Oncology, University of Milan, Milan; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano (Milan), Italy

Locatelli S.L. Medical Oncology, University of Milan, Milan; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano (Milan), Italy

Carlo-Stella C. Medical Oncology, University of Milan, Milan; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano (Milan), Italy

Chapter 17: Immunomodulatory Drugs and Cytokines

Haanen J. Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Blank C. Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

« Previous Page Next Page »

Last update: 02 August 2012